한글목차

TEZSPIRE(tezepelumab [AMG157])는 알레르기성 질환, 호산구성 질환 및 호흡기 염증성 질환의 발병과 지속에 중요한 역할을 하는 상피세포 사이토카인인 흉선간질림프포에틴(TSLP)의 작용을 억제하는 최초의 항체입니다. 아스트라제네카가 암젠과 공동 개발한 최초의 인간 단클론항체로서, TSLP, IL-25, IL-33은 상피에서 서로 다른 트리거에 따라 방출되어 Th2 염증 반응을 시작하고 Th2 세포에서 T 세포의 분극을 매개합니다. TSLP 억제 작용을 가진 테제페맙은 CSU 환자의 피부 병변을 예방하고 치료할 수 있는 것으로 생각됩니다.

이 보고서는 미국, EU 4개국(독일, 프랑스, 이탈리아, 스페인), 영국, 일본 등 주요 7개국의 CSU용 TEZSPIRE에 대한 2019년부터 2032년까지 상세한 분석 정보를 제공합니다. 또한 작용기전, 용법 및 용량, 규제 마일스톤을 포함한 연구개발 및 기타 개발 활동에 대한 인사이트를 제공합니다. 또한 주요 7개국 CSU용 TEZSPIRE 시장 예측 분석, SWOT, 애널리스트의 견해, 시장 경쟁업체에 대한 종합적인 개요, CSU용 다른 신흥 치료제에 대한 개요 등 향후 시장 평가도 포함하고 있습니다.

목차

제1장 보고서 소개

제2장 만성 특발성 두드러기(CSU)의 TEZSPIRE 개요

• 제품 상세
• 임상 개발
• 기타 발달 활동
• 제품 프로파일

제3장 경쟁 구도(출시된 치료법)

제4장 경쟁 구도(후기 단계 새로운 치료법)

제5장 TEZSPIRE 시장 평가

• 만성 특발성 두드러기(CSU)의 TEZSPIRE 시장 전망
• 주요 7개국 분석
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 보고서 구입 옵션

영문목차

"TEZSPIRE Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about TEZSPIRE for Chronic Spontaneous Urticaria (CSU) in the seven major markets. A detailed picture of the TEZSPIRE for CSU in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the TEZSPIRE for CSU. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the TEZSPIRE market forecast analysis for CSU in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in CSU.

Drug Summary:

TEZSPIRE (tezepelumab [AMG 157]) is being developed by AstraZeneca in collaboration with Amgen as a first-in-class human monoclonal antibody that inhibits the action of blocks thymic stromal lymphopoietin (TSLP), a key epithelial cytokine that sits at the top of multiple inflammatory cascades and is critical in the initiation and persistence of allergic, eosinophilic and airway inflammation diseases. TSLP, IL-25, and IL-33 are released following different triggers on epithelia and start the Th2 inflammatory response, mediating T-cell polarization in Th2 cells. Tezepelumab with its inhibitory action of TSLP appears to prevent and treat the lesional skin of patients with CSU.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the TEZSPIRE description, mechanism of action, dosage and administration, research and development activities in Chronic Spontaneous Urticaria (CSU).
• Elaborated details on TEZSPIRE regulatory milestones and other development activities have been provided in this report.
• The report also highlights the TEZSPIRE research and development activities in CSU across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around TEZSPIRE.
• The report contains forecasted sales of TEZSPIRE for CSU till 2032.
• Comprehensive coverage of the late-stage emerging therapies for CSU.
• The report also features the SWOT analysis with analyst views for TEZSPIRE in CSU.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

TEZSPIRE Analytical Perspective by DelveInsight

• In-depth TEZSPIRE Market Assessment

This report provides a detailed market assessment of TEZSPIRE for Chronic Spontaneous Urticaria (CSU) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.

• TEZSPIRE Clinical Assessment

The report provides the clinical trials information of TEZSPIRE for Chronic Spontaneous Urticaria (CSU) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Chronic Spontaneous Urticaria (CSU) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence TEZSPIRE dominance.
• Other emerging products for CSU are expected to give tough market competition to TEZSPIRE and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of TEZSPIRE in CSU.
• Our in-depth analysis of the forecasted sales data of TEZSPIRE from 2027 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the TEZSPIRE in CSU.

Key Questions:

• What is the product type, route of administration and mechanism of action of TEZSPIRE?
• What is the clinical trial status of the study related to TEZSPIRE in Chronic Spontaneous Urticaria (CSU) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the TEZSPIRE development?
• What are the key designations that have been granted to TEZSPIRE for CSU?
• What is the forecasted market scenario of TEZSPIRE for CSU?
• What are the forecasted sales of TEZSPIRE in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to TEZSPIRE for CSU?
• Which are the late-stage emerging therapies under development for the treatment of CSU?

Table of Contents

1. Report Introduction

2. TEZSPIRE Overview in Chronic Spontaneous Urticaria (CSU)

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. TEZSPIRE Market Assessment

• 5.1. Market Outlook of TEZSPIRE in Chronic Spontaneous Urticaria (CSU)
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of TEZSPIRE in the 7MM for Chronic Spontaneous Urticaria (CSU)
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of TEZSPIRE in the United States for Chronic Spontaneous Urticaria (CSU)
  • 5.3.2. Market Size of TEZSPIRE in Germany for Chronic Spontaneous Urticaria (CSU)
  • 5.3.3. Market Size of TEZSPIRE in France for Chronic Spontaneous Urticaria (CSU)
  • 5.3.4. Market Size of TEZSPIRE in Italy for Chronic Spontaneous Urticaria (CSU)
  • 5.3.5. Market Size of TEZSPIRE in Spain for Chronic Spontaneous Urticaria (CSU)
  • 5.3.6. Market Size of TEZSPIRE in the United Kingdom for Chronic Spontaneous Urticaria (CSU)
  • 5.3.7. Market Size of TEZSPIRE in Japan for Chronic Spontaneous Urticaria (CSU)

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options